Amgen, Inc. (AMGN), Regeneron Pharmaceuticals Inc (REGN), NPS Pharmaceuticals, Inc. (NPSP): Can These Biotechs Continue to Climb?

Eylea isn’t the only feather in Regeneron’s cap, though. The company partnered with Sanofi SA (ADR) (NYSE:SNY) on colorectal cancer drug Zaltrap, which gained FDA approval last August. While sales were sluggish initially, a steep price cut for the drug to make it more competitive should help.

Another collaboration with Sanofi holds longer term promise for Regeneron. In November, the two companies announced enrollment in a late-stage study of an antibody that targets lowering “bad” cholesterol. Should this study prove successful, Regeneron will have a rich new source of revenue in the next few years.

While NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have taken off in the past month, both stocks should be able to keep the momentum going for a while. However, any bumps in the road for Gattex or Eylea this year will demonstrate how applicable the theory of gravity is to the stock market. What goes up will come down — sooner or later.

The article Can These Biotechs Continue to Climb? originally appeared on Fool.com.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.